Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies

Global Leukodystrophy Initiative (GLIA) Consortium

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Leukodystrophies are a broad class of genetic disorders that result in disruption or destruction of central myelination. Although the mechanisms underlying these disorders are heterogeneous, there are many common symptoms that affect patients irrespective of the genetic diagnosis. The comfort and quality of life of these children is a primary goal that can complement efforts directed at curative therapies. Contained within this report is a systems-based approach to management of complications that result from leukodystrophies. We discuss the initial evaluation, identification of common medical issues, and management options to establish a comprehensive, standardized care approach. We will also address clinical topics relevant to select leukodystrophies, such as gallbladder pathology and adrenal insufficiency. The recommendations within this review rely on existing studies and consensus opinions and underscore the need for future research on evidence-based outcomes to better treat the manifestations of this unique set of genetic disorders.

Original languageEnglish (US)
Pages (from-to)18-32
Number of pages15
JournalMolecular Genetics and Metabolism
Issue number1-2
StatePublished - Sep 2017


  • Care
  • Consensus
  • Leukodystrophy
  • Outcomes
  • Prevention
  • Therapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology


Dive into the research topics of 'Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies'. Together they form a unique fingerprint.

Cite this